Labrys Biologics' Acquisition

Labrys Biologics was acquired by Teva Pharmaceuticals on July 21, 2014.

Labrys Biologics is a private, venture-financed development stage biotechnology company focused on the preventive treatment of migraine. Labrys' lead candidate, LBR-101 (formerly RN-307), is an anti-C…

Articles about Labrys Biologics' Acquisition: